Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort

Atrial FibrillationFurther Publications

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Circ Arrhythm Electrophysiol

Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L

doi: 10.1161/CIRCEP.125.014101

Atrial Fibrillation

Insomnia and the Risk of Atrial Fibrillation: A Nationwide, Real-World Cohort Study

J Am Heart Assoc

Masuda T, Ejiri K, Kaneko H, Suzuki Y, Miyoshi T, Taya S, Iwasaki K, Nakagawa K, Nishii N, Morita H, Okada A, Fujiu K, Takeda N, Morita H, Yasunaga H, Takeda N, Yuasa S

doi: 10.1161/JAHA.125.045149

Atrial FibrillationFurther Publications

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data

J Am Heart Assoc

Fath AR, Aglan A, Naidu SS, Mader MJ, Chilton RJ, Elgendy IY, Maron MS, Rowin EJ

doi: 10.1161/JAHA.125.045994

Heart, Artery and Coronary Diseases

Infective endocarditis in hypertrophic cardiomyopathy: a real-world matched cohort analysis

Heart

Rosenzveig A, Platek N, Massad F, Badwan O, Agrawal A, Menon V

doi: 10.1136/heartjnl-2026-327787

Atrial Fibrillation

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Heart Rhythm

Boriani G, McIntyre WF, Ramasundarahettige C, Proietti M, Glotzer TV, Diemberger I, Nielsen JC, Essebag V, Granger CB, Sandhu RK, Benezet-Mazuecos J, Mabo P, Coutu B, Wong JA, Gold MR, Lopes RD, Healey JS, ARTESiA Investigators

doi: 10.1016/j.hrthm.2025.07.002

Heart, Artery and Coronary Diseases

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Circ Genom Precis Med

Bilen O, Adler AS, Bastiaenen R, MacNamara JP, Paratz ED, Maor E, Arad M, Gold ME, Patel N, Pruett C, Burford E, Arora G, Maksabedian Hernandez EJ, Han X, Schuler P, Sandler B, Li L, Tian D, Arora P

doi: 10.1161/CIRCGEN.125.005502

Atrial Fibrillation

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation

J Am Heart Assoc

Lip GYH, Cheng D, Jiang J, Gao C, Subash R, Vodicka E, Dubey A, Sharma PP, Vettumthara Unnikrishnan A, Mathivanan K, Deitelzweig S

doi: 10.1161/JAHA.125.044113

Heart Failure

Prognostic Impact of Cardiovascular-Kidney-Metabolic Overlap Among Patients With Acute Heart Failure: Insights From a Real-World Multinational Cohort

J Am Heart Assoc

Marchetti M, Antiochos P, Pitta-Gros B, Abdurashidova T, Soborun N, Monney P, Yerly P, Tzimas G, Skalidis I, Vollenweider P, Gencer B, Fakhouri F, Vaduganathan M, Hullin R, Lu H

doi: 10.1161/JAHA.125.045294

Atrial Fibrillation

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Clin Res Cardiol

Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D, START2 Register Investigators

doi: 10.1007/s00392-025-02765-7

Related content

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Insomnia and the Risk of Atrial Fibrillation: A Nationwide, Real-World Cohort Study

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data

Infective endocarditis in hypertrophic cardiomyopathy: a real-world matched cohort analysis

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation

Prognostic Impact of Cardiovascular-Kidney-Metabolic Overlap Among Patients With Acute Heart Failure: Insights From a Real-World Multinational Cohort

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry